14-3-3 σ 抗体 (5D7): sc-100638

14-3-3 σ Antibody (5D7) is an IgG1 κ mouse monoclonal 14-3-3 σ antibody (also designated 14-3-3 σ antibody or 14-3-3 sigma antibody) that detects 14-3-3 σ of human origin by WB, IP, IF, IHC(P) and ELISA. 14-3-3 σ Antibody (5D7) is available as the non-conjugated anti-14-3-3 σ antibody form. 14-3-3 proteins regulate many cellular processes relevant to cancer biology, notably apoptosis, mitogenic signaling and cell-cycle checkpoints. Seven isoforms, denoted 14-3-3 b, g, e, z, h, q and s, comprise this family of signaling intermediates. 14-3-3 s, also known as SFN, stratifin, HME1 or YWHAS, is a secreted adaptor protein that is involved in regulating both general and specific signaling pathways. Expressed predominately in stratified squamous keratinising epithelium, 14-3-3 s is able to bind and modify the activity of a large number of proteins, such as KRT17 (Keratin 17), through recognition of a phosphothreonine or phosphoserine motif. When bound to Keratin 17, for example, 14-3-3 s acts to stimulate the Akt/mTOR signaling pathway by upregulating protein synthesis and cell growth. 14-3-3 s also functions to positively mediate IGF-I-induced cell cycle progression and can bind to a variety of translation initiation factors, thus controlling mitotic translation. In response to tumor growth, 14-3-3 s positively regulates the tumor suppressor p53 and increases the rate of p53-regulated inhibition of G2/M cell cycle progression. Multiple isoforms of 14-3-3 s exist due to alternative splicing events.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

References:

1. 14-3-3 sigma positively regulates p53 and suppresses tumor growth.  |  Yang, HY., et al. 2003. Mol Cell Biol. 23: 7096-107. PMID: 14517281
2. A structural basis for 14-3-3sigma functional specificity.  |  Wilker, EW., et al. 2005. J Biol Chem. 280: 18891-8. PMID: 15731107
3. 14-3-3sigma, a p53 regulator, suppresses tumor growth of nasopharyngeal carcinoma.  |  Yang, H., et al. 2006. Mol Cancer Ther. 5: 253-60. PMID: 16505098
4. CpG island promoter methylation and silencing of 14-3-3sigma gene expression in LNCaP and Tramp-C1 prostate cancer cell lines is associated with methyl-CpG-binding protein MBD2.  |  Pulukuri, SM. and Rao, JS. 2006. Oncogene. 25: 4559-72. PMID: 16786000
5. 14-3-3sigma controls mitotic translation to facilitate cytokinesis.  |  Wilker, EW., et al. 2007. Nature. 446: 329-32. PMID: 17361185
6. 14-3-3 sigma isoform interacts with the cytoplasmic domain of the transmembrane BP180 in keratinocytes.  |  Li, Y., et al. 2007. J Cell Physiol. 212: 675-81. PMID: 17443672
7. Methylation and intratumoural heterogeneity of 14-3-3 sigma in oral cancer.  |  Bhawal, UK., et al. 2007. Oncol Rep. 18: 817-24. PMID: 17786341
8. Over-expression of 14-3-3sigma in budding colorectal cancer cells modulates cell migration in the presence of tenascin-C.  |  Ide, M., et al. 2007. Oncol Rep. 18: 1451-6. PMID: 17982629
9. DNA methylation patterns of the CDH1, RARB, and SFN genes in choroid plexus tumors.  |  Losi-Guembarovski, R., et al. 2007. Cancer Genet Cytogenet. 179: 140-5. PMID: 18036402